Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
RegulatorypositiveolomorasibPositive
AI Analysis
Summary
Eli Lilly announced that olomorasib has received FDA Breakthrough Therapy designation as a monotherapy for treating previously treated KRAS G12C-mutant advanced pancreatic cancer, expediting development of the candidate.
Outcome Details
Breakthrough Therapy designation granted by FDA
Importance:8/10
Sentiment:
0.85
FDABreakthrough TherapyKRAS G12CPancreatic CancerMonotherapy
Related Companies
Read the original article
Published by PR Newswire Biotech on August 3, 2026 11:45 AM